Differentiation of Li-Fraumeni Syndrome (LFS) Patient-derived Induced Pluripotent Stem Cell (iPSC) to Mesenchymal Stem Cell (MSC) (Days 0 - 28)
2:19
iPSC-derived MSC Maturation (Day 28 - 45) and Differentiation of LFS MSC to Osteoblasts (Day 0 - 24)
4:33
Xenograft In Vivo Tumorigenesis Model Setup
6:39
Results: Representative LFS MSC Differentiation
8:10
Conclusion
Transcript
This Li-Fraumeni syndrome iPSC-based osteosarcoma model can help answer key questions in the osteosarcoma research field about using patient iP cells in cancer modeling. The main advantage of this model is that it allows the generation unlimited c
Sign in or start your free trial to access this content
Burada, bir protokol indüklenmiş pluripotent kök hücreler (iPSCs) üretimi için Li-Fraumeni sendromu (LFS) hasta türetilmiş fibroblastlar, iPSCs mezenkimal kök hücre (MSCs) yoluyla farklılaşma üzerinden dokusunu ve modelleme içinde vivo mevcut LFS hasta kaynaklı dokusunu kullanarak tumorigenesis.